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The global prevalence of hepatitis B virus is estimated to be 350 million chronic carriers, varying widely from low
(<2%, as in Western Europe, North America, New Zealand, Australia, and Japan) to high (>8% as in Africa, Southeast Asia,
and China). The overall prevalence in Brazil is about 8%. There are currently 7 genotypic variations, from A to G, and also
4 main surface antigen subtypes: adw, ayw, adr, and ayr. There has been great interest in identifying the geographic distribution
and prognosis associated with the various genotypes and subtypes. Although the serologic test is highly sensitive and
specific, it does not detect cases of mutant hepatitis B, which is increasingly common worldwide due to resistance and
vaccine escape, antiviral therapy, and immunosuppression, among other causes. Alterations in surface, polymerase, X
region, core, and precore genes have been described. The main mutations occur in surface and in core/precore genes, also
known as occult hepatitis, since its serologic markers of active infection (HBsAg) and viral replication (HBeAg) can be
negative. Thus, mutation should be suspected when serologic tests to hepatitis B show control of immunity or replication
coincident with worsened clinical status and exclusion of other causes of hepatitis.
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The hepatitis B virus (HBV) be-
longs to the Hepadnaviridae family
and the Orthohepadnavirus genus. It
measures 40 to 42 nm, has an external
surface envelope made up of proteins,
lipids, and carbohydrates, and has a
double-stranded circular DNA sur-
rounded by a hexagonal core region.
Although the virus is very resistant to
heat and other physical agents, in-
fected plasma can be inactivated by
heating it for 5 hours at 60°C. Hepati-
tis B virus infection may cause acute
hepatitis (leading to cirrhosis), fulmi-
nant hepatitis with massive hepatic
necrosis, an asymptomatic condition
(with or without progression of the
disease), or be a gateway to infection
by the hepatitis Delta virus.1
The worldwide prevalence is esti-
mated to be around 350 million
chronic carriers,2 with an annual inci-
dence of 300,000 new cases in the
United States of America (USA).3 The
overall prevalence estimates vary
widely from low (2%), as is found in
Western Europe, North America, New
Zealand, Australia, and Japan;5,6 inter-
mediate, as is found in Eastern Europe
(2% - 7%) and India (4%);5 high
(>8%), as found in Africa, Southeast
Asia, and China (15% and 20%), to
very high, as found in Tibetans in Ne-
pal (61%).4 Recent studies have shown
an incidence of 6.6% in Istanbul, Tur-
key,8 5.1% in Korea,9 4% in Singa-
pore,10 and 0.005% in Guangdong
Province, China.11 In Latin America,
the highest rates were found in the Do-
minican Republic (21.4%) and in Bra-
zil (7.9%), followed by Venezuela
(3.2%) and Argentina (2.1%). The low-
est ones were found in Mexico (1.4%)
and Chile (0.6%).12
Among the Brazilian regions, there
are variations from 66.1% in Western
Amazon,13 which is considered highly
endemic for HBV,7 40% in Rio de Ja-
neiro,14 21% in Manaus, and up to
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1.2% in Fortaleza. A study carried out
in the Afro-descendant community in
Mato Grosso do Sul revealed a preva-
lence of 42.7%,15 and a prevalence of
50.7% was found in individuals with
clinical evidence of hepatitis in
Goias.16
According to data from the Brazil-
ian Ministry of Health in the report
“Indicadores de Dados Básicos –
Brasil 2001” (IDB-2001),17 there was
an incidence of 7087 new cases in
2000, 540 of those in the state of São
Paulo. According to data from the Na-
tional Immunization Program, there
was a vaccine coverage of 2,710,493
inhabitants, with 23,157,823 doses ad-
ministered in the whole country in
1999.18
 The virus is transmitted especially
through bodily fluids, such as semen,
saliva, sweat, tears, or breast milk. Dur-
ing pregnancy, the virus may be trans-
mitted to the fetus by crossing the pla-
cental barrier or also through cellular
transmission.19 Although there is evi-
dence of HBV infection in animals,
there is no evidence of zoonotic trans-
mission.20
The primary risk categories for in-
fection by HBV are transfusions, blood
derivates, dialysis, needle accidents
among health-care professionals, intra-
venous drug abuse, and among homo-
sexual individuals. Data published in
2002 showed an active infection with
HBV of about 1.7% of 3556 heath-care
workers in Chandirgarh, China.21 In
Lagos, Nigeria, a study in 2000 found
a prevalence of active infection by
HBV of 25.7% in surgeons compared
to 15% in administrative staff (control
group).22
Vertical transmission is common in
endemic regions such as Africa and
Southeast Asia.3 A report from CDC
(Centers for Disease Control and Pre-
vention) in the United States estimated
an incidence of 0.60% among preg-
nant white non-Hispanics, 0.97%
among black non-Hispanics, 0.14%
among Hispanics, and 5.79% among
Asians. A factor associated with in-
creased rates was not receiving prena-
tal care.23 Another study conducted in
Saudi Arabia found HBV causing 15%
of the sporadic acute viral hepatitis in
pregnancy.24 Infants who acquire HBV
perinatally have up to a 90% risk of
developing HBV infection.25
Figure 1 shows the HBV genome.
Proteins of greater importance pro-
duced by the HBV are:
• Nucleocapsid core protein
(HBcAg), which is not detectable
in the serum;
• Long polypeptide “e” (AgHBe),
which is transcribed from the core
and precore genomic regions dur-
ing active viral replication;
• Envelope glycoprotein (HBsAg)
indicating active infection;
• A DNA polymerase with reverse
transcriptase activity used by the
virus upon cell infection;
• A protein from the X region that is
necessary for replication and tran-
scriptional transactivation of the
viral genes and has a key role in
the development of hepatocellular
carcinoma (HCC).
Envelope glycoprotein contains a
constant and group-specific epitope
designated “a” and at least 2 variable
epitopes, which are group-specific:
“d” or “y” and “w” or “r”, allowing for
the identification of 4 antigenic
subtypes: adw, ayw, adr, and ayr. The
ad subtypes are frequently found in
asymptomatic individuals, whereas in
the acute form the ay and ad subtypes
may be found. A study in Goias (2002)
found in individuals with clinical evi-
dence of hepatitis a laboratory confir-
mation of ay and ad subtype
prevalences of 23.5% and 62.7%, re-
spectively.16 The ay subtype is found
in drug abusers and dialysis patients.
Currently, enzyme immunoassay
methods (EIA) are available for
subtype determination. These assays
have several applications such as for
large epidemiologic studies and as a
substitute for nucleotide sequencing,
which is not adapted for large-scale
Figure 1 - Representation of DNA- Hepatitis
B virus structure: adapted from Robbins,
Pathologic Basis of Disease, 1999, pg 858.
Figure 2 - Global vaccination coverage against H hepatitis B virus. World Health Organization,
2003.
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screening and not applicable on sam-
ples from nonviremic HBV carriers.26
There are 7 genotypic variations
for HBV, named from A to G,1 which
have been associated with geographic
distribution and with the progression
of hepatic disease. The current ten-
dency is to identify the more prevalent
type to correlate to clinical findings.
In southern Taiwan, the most common
genotypes found were B (60%) and C
(34%), the latter being associated with
more severe liver disease.27 However,
the life-long risk of progression to ad-
vanced fibrosis and development of
HCC may not differ among genotypes
B- and C-related chronic liver dis-
ease.28 A retrospective study done in
Amsterdam from 1992 to 1997 associ-
ated genotype A with homosexual men
and genotype D with intravenous drug
users.29
The mechanism of injury after in-
fection of the hepatocytes by HBV is
not clearly established. Some evidence
indicates that cytotoxic T cells di-
rected towards the HBcAg antigen that
is expressed on the cell surface may
lead to hepatocyte destruction.
The asymptomatic incubation pe-
riod varies from 4 to 26 weeks, fol-
lowed by acute disease lasting from a
few weeks to 6 months. In the post-
transfusional infections, the incuba-
tion period may vary from 12 to 14
weeks.
The serologic markers are:
1. HBsAg—appears before the onset
of symptoms, peaks during overt
disease, and declines after 3 to 6
weeks;
2. HBeAg—appears in the serum in-
dicating active viral replication.
There is a significant correlation of
HBeAg with HBV DNA (through
PCR) and DNA polymerase;
3. Anti-HBc IgM—detectable in the
serum shortly after the onset of
symptoms, along with the eleva-
tion of serum transaminases and
HBsAg and HBeAg. Anti-HBc IgM
represents the first sign of an im-
mune response after infection by
the HBV, since it comes before the
detection of anti-HBs and anti-
HBe. Over ensuing months, IgM is
replaced by anti-HBc IgG. If
HBsAg or HBeAg cannot be de-
tected, anti-HBc may the only se-
rologic marker that points towards
a present or past HBV infection, as
well as potentially contaminated
blood. Thus, anti-HBc is a sero-
logic marker for contact with HBV.
4. Anti-HBe—detectable in sera soon
after the decline of HBeAg, indi-
cating the peak of acute disease
and suggesting that the disease is
near remission, with titers declin-
ing after 20 weeks;
5. Anti-HBs—its levels do not de-
cline until acute disease is over and
may even last for a lifetime, con-
ferring immunity.
In adults, 90% to 95% of HBV in-
fections have a spontaneous remission,
with anti-HBc and anti-HBs detected
in serologic tests for a long period. In
asymptomatic carriers, HBsAg may be
present alone, without viral replication
and hepatic damage. Patients with a
chronic evolution (5% - 10%) may
present with a persistent chronic hepa-
titis of a self-limiting nature or, as in
3% of the cases, with active replica-
tion and poor outcome, characterized
by the presence of HBsAg, HBeAg,
HBV DNA, and usually total anti-HBc.
Progressive liver damage may occur,
leading to cirrhosis and HCC, increas-
ing the risk of death.30 An Indian study
found HBV infection in 70% of the
cases of chronic hepatitis, 80% of he-
patic cirrhosis, and 60% of HCC.5 Nev-
ertheless, these situations can be sim-
ply avoided with mass vaccination
program.31
Two types of products are avail-
able for prophylaxis against HBV in-
fection. Hepatitis B immune globulin
(HBIG) provides temporary protection
(ie, 3 to 6 months) and is indicated
only in certain postexposure settings,
and hepatitis B vaccine provides long-
term protection against HBV infection
and is recommended for both
preexposure and postexposure prophy-
laxis.73
Hepatitis B immune globulin is
prepared from plasma known to con-
tain a high titer of antibody against
HBsAg (anti-HBs). In the United States,
HBIG has an anti-HBs titer of
>100,000 by radioimmunoassay. The
human plasma from which HBIG is
prepared is screened for antibodies to
HIV; in addition, the process used to
prepare HBIG inactivates and elimi-
nates HIV from the final product. There
is no evidence that HIV can be trans-
mitted by HBIG.79,80
Vaccination is highly effective.
Hepatitis B vaccines are composed of
the HBsAg polypeptide that is pro-
duced in yeasts by the recombinant
DNA technique or is artificially syn-
thesized, and they are packaged to
contain 10 to 40 ug of HBsAg protein/
mL after adsorption to aluminum hy-
droxide (0.5 mg/mL); thimerosal
(1:20,000 concentration) is added as a
preservative.73 The recommended se-
ries of 3 intramuscular doses of hepa-
titis B vaccine induces a protective
antibody response with 90% to 95%
efficacy in preventing HBV infection
and its chronic sequelae. Currently li-
censed hepatitis B vaccines include
Recombivax HB® and Engerix-B®.75
Initially administered to higher risk
populations, such as health-care pro-
fessionals, contacts to chronic carriers,
newborns from infected mothers, and
homosexual men, the vaccine pro-
tected many individuals but had little
impact on the total number of infected
persons. Thus, a pediatric vaccine was
manufactured that was given along
with the MMR vaccine to children in
the high-risk groups, with a WHO rec-
ommendation for all countries to inte-
grate hepatitis B vaccination into their
universal childhood vaccination pro-
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grams by 1997.73 It is known that
childhood vaccination can protect
children against fulminant hepatitis
and HCC1; however, to prevent perina-
tal HBV transmission, the first dose of
vaccine should be administered within
the first 24 hours after birth.73,74 Unpub-
lished data from the CDC from 2003
shows that approximately 21% of
HBV-related deaths result from infec-
tion acquired in the perinatal period
and 48% from infection acquired in
early childhood (age <5 years). There-
fore, vaccination of infants and chil-
dren is the highest priority for hepati-
tis B vaccination programs. Some ex-
amples of vaccination program effec-
tiveness include the Canadian results,
with a HBV prevalence of 0.0038%
during the period 1993 to 199533, and
the United States results, with a decline
of 76.1% after 11 years of the program,
having rates of 0.033% in 1998.3 In
The Gambia, the prevalence of chronic
infection among children declined
from 10.0% to 0.6% after implemen-
tation of universal infant hepatitis B
vaccination.76 Similar declines in
prevalence of chronic infection asso-
ciated with infant and childhood hepa-
titis B vaccination have been demon-
strated in China, Indonesia, Senegal,
and Thailand, and among Alaska Na-
tives.77,78 According to the WHO esti-
mate, a total of 151 (79%) of 192
member states had adopted universal
childhood hepatitis B vaccination
policies. In the 6 WHO regions, the
proportion of children aged <1 year
who were vaccinated fully was 65% in
the Western Pacific Region, 58% in
the Americas Region, 45% in the Eu-
ropean region, 41% in the Eastern
Mediterranean region, 9% in the
Southeast Asia region, and 6% in the
African region. Even so, only 32% of
children aged <1 year were vaccinated
fully with the 3-dose hepatitis B vac-
cination series.75
Serologic tests carried out after im-
munization are intended to evaluate
immunity, identifying nonresponsive
or weak-response individuals. A re-
sponse is considered absent whenever
anti-HBs titers are less than 10 UI/L
and weak when titers are less than 100
UI/L36. Immunized people may lose
anti-HBs antibodies over variable
courses of time, and initial antibody
concentration after immunization may
allow the prediction of the period dur-
ing which the person will be immune
as well as the scheduling of a date for
revaccination.
Recent innovations have included
the 2-dose, 10 mg Recombivax HB®
regimen for those who are 11 to 15
years old and Twinrix®, a combination
hepatitis A and B vaccine.81 Goals for
global hepatitis B vaccination are for
the vaccine to be introduced in all
countries by 2007, for coverage with
the 3-dose hepatitis B vaccination se-
ries to reach 90% by 2010,72 and for
the total control in first half of the 21st
century.1
Figure 3 shows a current algorithm
for serological diagnosis of HBV used
in Immunological Section of Central
Clinical Laboratory Division of Clinic
Hospital of University of São Paulo
Medical School (HC-FMUSP). The se-
rologic marker for contact is total anti-
HBc (IgM and IgG). A negative test in-
dicates no previous contact with HBV
and thus excludes current infection. A
positive test requires evaluation for
anti-HBs and HbsAg, which will indi-
cate either immunity or active infec-
tion. If the latter is confirmed, the pres-
ence of anti-HBe, HbeAg, and anti-HBc
Figure 3 - Suggested algorithm for serologic diagnosis of Hepatitis B virus (HBV).
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(IgM) must be determined, which will
indicate the probable evolution of the
disease. Anti-HBs tests can be per-
formed separately when the purpose is
to evaluate the immunological status
of a patient against HBV infection, ie,
whether there was previous vaccina-
tion or not.
Although these EIA tests are highly
sensitive and specific, their interpreta-
tion should be done considering clini-
cal and epidemiological status. In
cases with serologic markers indicat-
ing immunity or cessation of replica-
tion with other causes of hepatitis ex-
cluded, a genomic mutation of HBV—
also known as occult hepatitis—has to
be suspected. The presence of normal
transaminase and low levels of HBV-
DNA does not exclude the existence
of resistant mutants.37
Mutations have been described in
several regions of viral DNA, includ-
ing surface gene, X gene, core gene,
polymerase gene, and precore gene.
The main mutations occur in the sur-
face genes, which encode epitopes neu-
tralized by antibodies, and in precore/
core genes, which encode epitopes pre-
sented to CD8 T cells.39
Genetic transformation can be de-
tected by the following tests: PCR
(polymerase chain reaction),39 bDNA
(branched DNA assay),40 PCR-RFLP
(PCR followed by restriction length
polymorphism assay),41 msPCR (mu-
tant-specific PCR),42 CMSSA (com-
petitive mutation site-specific
assay),41or MSSA (mutant site-specific
assay).43
Serologic assays do not reveal ge-
nomic transformation; PCR is more
sensitive than bDNA;44 CMSSA is
more sensitive and specific than PCR-
RFLP, mainly for detecting precore
mutants; and msPCR is more sensitive
and specific than other similar assays.
In addition, other PCR variations are
being tested to detect mutants. SP-PCR
(sequence-specific PCR) and LDR-
PCR (limiting dilution-cloning PCR)
are some examples, the latter having
the greatest sensitivity for detecting
variants in the surface antigen.45
Surface antigen mutations occur in
pre-S1/2 and S regions, also known as
escape or immune escape mutations.46
They are characterized by either posi-
tive HBsAg and anti-HBs or negative
HBsAg with positive anti-HBs, occur-
ring mainly in chronic hepatitis carri-
ers.48 An international study that in-
volved investigators from CDC and
WHO demonstrated a prevalence of
51% in variants of surface antigen
among infants with chronic HBV in-
fection.45 Pre-S1 epitope has been pos-
sibly related to virus replication (posi-
tive HBeAg), even with the presence
of anti-HBe. In turn, the pre-S2 epitope
has not been related to virus replica-
tion levels.49 But in the case of the S
epitope, this mutation decreases or
abolishes the HBsAg properties, prob-
ably inhibiting its transcription levels.
This explains a persistence in the natu-
ral course of the HBV infection50 co-
incidentally with having negative
HBsAg and positive anti-HBs sero-
logic results.48 In addition, advanced
hepatic fibrosis and diminished re-
sponse to interferon alpha can occur.51
Precore/core gene transformations
have generally been associated with
chronic HBV infection,38, 41, 52-58 having
serologic results with either positive
HBeAg40-42,47,52,53,57-60 or negative
HBeAg.54 The latter have been more
frequently reported,46,61 also known as
an e-minus mutation. Frequently, the
mutation occurs after seroconversion
to anti-HBe.42
Mutations that produce a stop
codon in the precore region of HBV
DNA are usually point mutations, with
a single nucleotide (nt) substitution.
Currently, mutations have been re-
ported in nt 1762 (A to T), 1764 (G to
A), 1835 (A to C), 1896 (G to A),
1857, and 1897 among others.38,62,63
One of the most prevalent is the
precore nt 1896 mutation.38,62,63 Sero-
logic markers include positive HBeAg/
anti-HBe39,41,47,58 as well as negative
HBeAg,38,53,54 both in chronic hepati-
tis B patients. Precore mutations can
also be related to fulminant or severe
hepatitis, and their absence in HBeAg-
positive patients indicates a good
prognosis.43,62
Core mutations possibly alter the
transcription factor-binding site, in-
creasing the activity of core promoter
related to HBV reactivation,57 HCC,
and hepatic cirrhosis. Investigators
from China have reported that the pres-
ence of core promoter mutations were
significantly more common in HCC
patients than asymptomatic carriers
and also were more common in pa-
tients with cirrhosis and chronic hepa-
titis.64 The prevalence of both types of
chronic hepatitis e-minus (e-CHB) mu-
tations varies according to worldwide
region. A literature review, which in-
cluded 50 studies, found the highest
rates in Far East and Mediterranean
countries54 – about 33%—followed by
15% in Asia Pacific and 14% in the
USA and Northern Europe.65 The
precore stop-codon variant was de-
tected in a median of 60% (range 0-
100%) of HBeAg-negative patients
overall, 92% in the Mediterranean,
50% in Asia Pacific, 27% in Gambia
and 25%, and 24% in the USA and
Northern Europe.63,65
The main causes of genetic varia-
tion have been related to the escape
mechanism and to viral resistance and
have been associated with:
1. Natural infection (mainly novel
surface mutations)48;
2. Vaccination (mutation in surface
antigen47,66-68) or presence of anti-
bodies against dominant B cell
epitopes69;
3. Antiviral therapy (activation of
HBV genetic mutant variants dur-
ing lamivudine treatment or
chemotherapy or associated with
acute liver disease62,66,67,69). A study
carried out in India found a fre-
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quency of 29% of lamivudine–re-
sistant HBV variants with muta-
tions in the surface and polymer-
ase genes 18 month after
lamivudine therapy.37 Another
study relates the reactivation of
HBV with a precore mutation (nt
1896) with cytotoxic chemo-
therapy, suggesting the need for a
prophylactic use of lamivudine be-
fore and during the chemotherapy
for patients with precore mutant
varieties of HBV62;
4. Immunosuppression associated
with HBV infection (mutation in
different types and positions: core,
pre-S1/2, X gene70);
5. Chronic hepatis B followed by
liver,56-71 renal,53,59 or bone marrow56
transplantation;
In most of the cases, genetic varia-
tion occurs concomitant with wild
strains, it rarely occurs isolated.47,54
Figure 4 suggests an algorithm for
serologic diagnosis with suspicion of
mutation, which must be confirmed
with further exams, such as molecular
typing.
Mutations can therefore affect the
natural course of HBV infection, viral
clearance, and antiviral therapy re-
sponse. The exact contributions of spe-
cific genetic variations, diagnosis, and
proper therapy still have to be
estabilished.47
Figure 4 - Suggestion of algorithm for anomalous serologic markers. (suspicion of Hepatitis B
virus (HBV) mutants).
RESUMO
Khouri ME e col. Hepatite B: consi-
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2004.
A prevalência mundial do vírus da
Hepatite B é estimada em cerca 350
milhões de infectados cronicamente,
tendo distribuição bastante variada
com prevalências baixas desde inferi-
ores a dois por cento, como Europa
Ocidental, América do Norte, Nova
Zelândia, Austrália e Japão – até altas,
superiores a oito por cento como en-
contradas na África, Sudeste Asiático
e China. No Brasil, a prevalência mé-
dia é em torno de 8%. São descritos
atualmente sete variações genotípicas
do HBV, nomeadas de A a G, e quatro
subtipos principais de antígenos de
superfície: “adw”, “ayw”, “adr “e
“ayr”, existindo um grande interesse
em identificar quais os subtipos e
genotipos mais prevalentes a fim de
correlacioná-los com manifestações
clínicas e distribuição geográfica. Ape-
sar do diagnóstico sorológico ser nor-
malmente bastante sensível e especí-
fico, este não detecta casos de Hepati-
te B mutantes, cada vez mais freqüen-
tes atualmente devido a escape e resis-
tência de vacinação, terapias anti-
virais, imunossupressão dentre outras.
São descritas alterações genômicas no
gene de superfície (envelope); gene X;
gene do “core”; gene polimerase e
gene “pré-core”. As principais muta-
ções ocorrem nos genes de superfície
e nos genes “pré-core/core”, podendo
também ser conhecidas como hepati-
te oculta, uma vez que os marcadores
de infecção ativa (AgHBs) e replicação
viral (AgHBe) podem estar negativos.
Assim, deve-se suspeitar de mutação
viral nos casos em que a sorologia para
a hepatite B indica imunidade ou pa-
rada da replicação com o quadro clí-
nico evoluindo mal, excluído outras
causas de hepatites.
UNITERMOS: Hepatite B.
Epidemiologia. Serologia. Mutação.
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